Daxor

Daxor Corporation's mission is to advance healthcare by enabling optimal fluid management through its proprietary Blood Volume Analysis (BVA) technology. The company has achieved FDA clearance for its next-generation Daxor BVA Analyzer, built on a foundation of over 75,000 tests and 175+ peer-reviewed studies demonstrating improved outcomes in heart failure and ICU settings. Its strategy centers on commercializing this rapid, portable system to address the 'silent crisis' of volume mismanagement in value-based care, leveraging its U.S. manufacturing facility for scale.

Patented Blood Volume Analyzer (BVA) systems based on indicator dilution using iodine-131 radiolabeled human serum albumin (RISA) to directly and accurately measure total blood volume, red cell volume, and plasma volume.

Daxor has no direct competitor offering an FDA-cleared device for direct blood volume measurement. Its main competition is the entrenched standard of care using imprecise surrogates. Adjacent technologies like non-invasive hemodynamic monitors or bioimpedance devices are indirect and not substitutive, giving Daxor a strong first-mover moat.